探索二皮里米衍生物作为碳水化合物催化酶调节剂,以减轻糖尿病
Syed Parween Ali1, Farheen Mansoor2, Shaymaa Fadhel Abbas Albaayit3
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 62529, Saudi Arabia.
Scientific reports
|December 31, 2024
概括
这项研究确定了34种二皮里米衍生物作为糖尿病管理中的强效α-葡萄糖酶抑制剂. 化合物5显示出显著的活性和安全性,提供了一个有前途的治疗候选者.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是一种全球性健康问题,其特点是高血糖.
- 阿尔法-葡萄糖酶抑制是管理食后高血糖症的关键策略.
- 二皮里米是一种具有已知的治疗潜力的化合物,包括抗糖尿病性质.
研究的目的:
- 为了评估37个二皮里米衍生物的图书馆,以评估它们作为α-葡萄糖酶抑制剂的潜力.
- 通过向碳水化合物代谢来确定用于糖尿病管理的新型化合物.
主要方法:
- 在体外对37种二皮里米衍生物进行查,以对抗α-glucosidase.
- 对化合物的酶动力学和细胞毒性测定.
- 计算对接研究以阐明绑定相互作用.
主要成果:
- 34种衍生品表现出显著的α-葡萄糖酶抑制活性 (IC50:5.3056.72μM).
- 化合物5在BJ细胞系中显示出高强度 (IC50: 5.30μM),竞争性抑制 (Ki: 16.10μM),并且没有细胞毒性.
- 计算分析显示,衍生品和α-葡萄糖酶之间存在有利的结合相互作用.
结论:
- 二皮里米衍生物代表了一类有前途的α-葡萄糖酶抑制剂.
- 化合物5是糖尿病治疗进一步发展的强效,安全和可行的候选药物.
- 这些发现支持二皮里米在治疗糖尿病方面的治疗潜力.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Overview of Carbohydrate Metabolism
724
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
724
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136


